Madrigal Pharmaceuticals, Inc.

MDGL Healthcare Biotechnology

Madrigal Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $958.4 million, up 432.1% from fiscal 2024.

Revenue
+50.1%
EPS
+147.3%
Free cash flow
+53.5%
Total debt
+0.45%

Quarter to September 2026, against a year earlier

390.52 9.58 −2.39%
Market cap
$9.3B
P/E
0.0×
Fwd P/E
−68.8×
Dividend yield
—
F-score
n/a
Altman Z
10.48
Beneish M
0.50
Dividend safety
n/a

Madrigal Pharmaceuticals, Inc. (MDGL) Gross margin

Alert me on Gross margin

Madrigal Pharmaceuticals, Inc.'s gross margin over the twelve months to 30 September 2026 was 91.0%, down 3.2 percentage points from fiscal 2025 (94.1%). Over the past ten years it has ranged from 0.00% (fiscal 2022) to 96.5% (fiscal 2024); the current reading is higher than 89% of that period. That is above the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.9%.

Gross margin, annual

Embed this chart

Annual newest first

Period Gross margin Change (points)
FY2025 94.1% (2.40)
FY2024 96.5% 96.54
FY2022 0.00% 0.00
FY2021 0.00% 0.00
FY2020 0.00% 0.00
FY2019 0.00% 0.00
FY2018 0.00% 0.00
FY2017 0.00% 0.00
FY2016 0.00% —

Quarterly newest first

Period Gross margin Change (points)
Sep 2026 91.2% 2.21
Jun 2026 89.0% (2.36)
Mar 2026 91.4% (1.01)
Dec 2025 92.4% (1.30)
22 more quarters

Against its own ten years

Low 0.00% High 96.5%
Ten-year median 0.00%
Current reading's percentile 89

Gross margin against peers

What Gross margin is

Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.

Gross Profit ÷ Revenue

The full definition of Gross margin →

More on MDGL